SCHEDULE: Invus Public Equities Group Discloses 10.6% Stake in Inventiva S.A.
Beneficial Ownership Report
Invus Public Equities, along with affiliated entities and Raymond Debbane, has reported a 10.6% beneficial ownership stake in Inventiva S.A., totaling 14,814,813 ordinary shares.
Summary
- Invus Public Equities, L.P., and its related entities (Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and Raymond Debbane) collectively reported beneficial ownership of 14,814,813 ordinary shares of Inventiva S.A.
- This represents 10.6% of Inventiva S.A.'s outstanding shares.
- The calculation is based on 139,151,274 shares outstanding as of May 5, 2025, as reported by Inventiva S.A. in its Form 6-K.
- The shares are ordinary shares with a nominal value of Euro 0.01 per share, with each American Depositary Share (ADS) representing one ordinary share.
Sentiment
Score: 6
Explanation: The filing is a standard beneficial ownership report, indicating a significant stake held by Invus Public Equities and its affiliates in Inventiva S.A. While the holding itself is a positive signal of investor confidence, the document provides no operational or financial performance details to assess sentiment beyond the ownership structure.
Positives
- A significant institutional investor group, Invus Public Equities, holds a substantial stake, indicating confidence in Inventiva S.A.
- The beneficial ownership is concentrated with sole voting and dispositive power held by the reporting persons, suggesting a unified investment strategy.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by a private equity group in a biotechnology company. Such investments can signal long-term confidence in the company's pipeline or market position within the pharmaceutical or biotech sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder may provide a sense of stability or validation for other investors.
- Company Management: Awareness of a large, concentrated ownership stake may influence strategic decisions or engagement with this investor group.
Key Dates
| Date | Description |
|---|---|
| 2025-05-05 | Date Inventiva S.A. reported 139,151,274 shares outstanding in its Form 6-K. |
| 2025-06-30 | Date of event requiring the filing of this statement, reflecting the beneficial ownership position. |
| 2025-07-31 | Date the Schedule 13G/A filing was signed. |
Keywords
Inventiva S.A., IVA, Invus Public Equities, Beneficial Ownership, Schedule 13G, Biotechnology, Pharmaceuticals, Investment, Shareholder, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.